Summit on Challenges and Solutions in Quality & Safety of Homeopathic Drug Products

June 27-28, 2019 | Hilton Baltimore Inner Harbor

Safety Track: Workshop 3
3:00–4:30 p.m.

Part II: Application of General Toxicology Studies to Support Regulatory Requirements
Presented by Matthew D. Reed, PhD, DABT, Fellow ATS, Principal, Coelus LLC

Public safety is FDA's top priority, as it should be for manufacturers too. Building upon the previous Safety Workshop, Dr. Reed will detail how toxicology is utilized to determine safe starting doses for human use comparing and contrasting pharmaceutical and homeopathic approaches. Is your company worried about potential litigation regarding the safety of your products? Matt's presentation will equip your company with the tools and background to make a rational and science-based justification that your products are safely formulated for sale to consumers.

What You Will Learn:

- Principles of toxicology testing applied to product development.
- How these methods are used to support safe human starting doses.
- Comparing and contrasting pharmaceutical and homeopathic approaches.

About the Presenter
Matt Reed is the Principal and CEO of Coelus LLC where he facilitates full phase development of pharmaceutical IP and provides consulting services in toxicology, pharmacology, and hazard assessment. Dr. Reed is a pharmacologist, board certified toxicologist, ABT Board Member, and Fellow-Academy of Toxicology Sciences (ATS). He has more than 25 years' experience having successfully transitioned multiple R&D programs through regulatory registration milestones.